WP1244 / CNS Pharma, UT MD Anderson Cancer Center - LARVOL DELTA

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update (PRNewswire) - "The Company's development work has produced a new mesylate salt of WP1244, now identified as WP1874. The enhanced solubility of this salt may increase its ability to be formulated for use in an IV infusion, while maintaining similar potency and toxicity characteristics. Going forward, WP1874 will be the primary focus in our development efforts of the WP1244 portfolio. CNS Pharmaceuticals is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas...Upcoming Milestones....File IND in 2023."

IND • Pipeline update • Brain Cancer • CNS Tumor • Oncology • Solid Tumor

WP1874, a highly potent unique DNA binding agent with enhanced CNS uptake (SNO 2021) - "We have discovered compound WP1244 that potentially binds up to 10 bp long sequences of DNA...WP1874, similarly to its parental compound, shows high cytotoxicity in ependymoma, GBM, and medulloblastoma cell lines with IC 50 in low nanomolar range and it was up to 100 to 200 times more potent than doxorubicin...Intraperitoneal administration was well-tolerated up to 5 mg/kg given three times a week for four cycles. High CNS uptake, excellent cytotoxicity against different brain cancer cell lines, and low toxicity in vivo and in vitro against normal cells warrant further investigation of WP1874 as a mechanically unique potential anticancer agent against CNS malignancies."

Brain Cancer • CNS Tumor • Ependymoma • Glioblastoma • Medulloblastoma • Oncology • Solid Tumor

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook (PRNewswire) - “Berubicin Development in the U.S: Commence patient dosing in potentially pivotal study to evaluate efficacy of Berubicin in the treatment of adult GBM in Q3 2021; Berubicin Development in the EU with Sublicensee Partner: Initiate Phase 2 multicenter clinical trial of Berubicin in adults with GBM in the second half of 2021; Initiate Phase 1 pediatric study in the second half of 2021; and Interim analysis of the first 18 patients in adult Phase 2 study expected in 2022; WP1244 Upcoming Milestones: File IND in 2022.”

IND • New P1 trial • P2 data • Trial status • Glioblastoma • Oncology

[VIRTUAL] Multivalent targeted cytolytic agents for glioblastoma treatment (SNO 2020) - "QUAD 3.0 was conjugated to a modified form of Pseudomonas Exotoxin A (PE38QQR) and highly potent DNA binding agents based on modified doxorubicin (WP936, WP1737 and WP1244). Thus, multivalent targeted agents demonstrate highly promising anti-tumor activity as single pharmaceutical, off-the-shelf agents. We also expect that our targeted drug candidates produce immune responses against tumors amplifying their cytolytic anti-tumor effect"

Glioblastoma • Oncology • Solid Tumor • Targeted Protein Degradation • EPHA2 • EPHA3 • EPHB2 • IL13

CNS Pharmaceuticals announces sponsored research agreement with MD Anderson for potential cancer treatment technologies (PRNewswire) - "CNS Pharmaceuticals, Inc…announces it has entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center relating to potential cancer treatment technologies, including WP1244, a novel DNA binding agent that is up to 500-times more potent than the clinically used chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation."

Licensing / partnership • Oncology

CNS Pharmaceuticals announces shareholder webinar to discuss collaboration with WPD Pharmaceuticals for developing coronavirus drug candidates, the significance of WP1244, and an update on the cancer free survivor treated with berubicin (PRNewswire) - “CNS Pharmaceuticals, Inc…announced that CEO, John M. Climaco, will be issuing a shareholder webinar on April 22nd, 2020 at 4:30pm ET to discuss the Company's novel DNA-binding agent, WP1244, and to provide an update on both the development of WP1122 through its strong relationship with WPD Pharmaceuticals in Poland, and a glioblastoma survivor treated with Berubicin.”

Clinical • Licensing / partnership • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor